Pacira Aims For Non-Opioid Pipeline Growth With Flexion Buy

Deal Worth About $427.5m Upfront

 
• By Alaric DeArment

Flexion’s Zilretta is forecast to have big market potential with the growth of osteoarthritis, and Pacira’s CEO suggested there were commercial synergies with its Iovera device.

Film x-ray knee joint with arthritis
Pacira is acquiring Flexion in a deal worth about $427.5m • Source: Shutterstock

More from Deals

More from Business